Published in Nat Med on September 21, 2010
Neurodegeneration and the neurovascular unit. Nat Med (2010) 1.37
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm (Vienna) (2011) 1.04
Neurotrophic natural products: chemistry and biology. Angew Chem Int Ed Engl (2013) 0.96
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics (2014) 0.92
Neurodegeneration and the neuroimmune system. Nat Med (2010) 0.86
Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry (2013) 0.78
Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol. Cell Stress Chaperones (2016) 0.78
Computer keyboard interaction as an indicator of early Parkinson's disease. Sci Rep (2016) 0.76
Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed? J Neural Transm (Vienna) (2012) 0.75
Learning from genetic forms of neurodegeneration. Nat Med (2010) 0.75
Differential Targeting of Hsp70 Heat Shock Proteins HSPA6 and HSPA1A with Components of a Protein Disaggregation/Refolding Machine in Differentiated Human Neuronal Cells following Thermal Stress. Front Neurosci (2017) 0.75
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology (2006) 6.86
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology (2007) 3.62
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA (2002) 3.46
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med (1989) 2.97
Probing the biology of Alzheimer's disease in mice. Neuron (2010) 2.96
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Looking backward to move forward: early detection of neurodegenerative disorders. Science (2003) 2.65
A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology (2007) 2.32
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2006) 1.95
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord (1997) 1.62
Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord (2008) 1.61
Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 1.61
Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci (2010) 1.50
Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol (2008) 1.47
The delayed-start study design. N Engl J Med (2009) 1.45
Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol (2007) 1.42
Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord (2007) 1.41
The effect of age of onset of PD on risk of dementia. J Neurol (2007) 1.14
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement (2009) 1.13
Premotor Parkinson's disease: clinical features, detection, and prospects for treatment. Ann Neurol (2008) 1.10
Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol (2008) 1.09
The early diagnosis of Parkinson's disease. Ann Neurol (1998) 1.07
Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS J (2010) 1.06
Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol (2005) 1.04
Issues in neuroprotection clinical trials in Parkinson's disease. Neurology (2006) 0.99
A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci (2005) 0.99
Using global statistical tests in long-term Parkinson's disease clinical trials. Mov Disord (2009) 0.98
[18 F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology (2000) 0.95
The relationship of Parkinson disease with aging. Arch Neurol (2007) 0.95
Hyposmia and executive dysfunction as predictors of future Parkinson's disease: a prospective study. Mov Disord (2009) 0.90
Chipping away at diagnostics for neurodegenerative diseases. Neurobiol Dis (2009) 0.89
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord (2009) 0.89
Neuroprotection in Parkinson's disease: and now for something completely different? Lancet Neurol (2006) 0.89
Searching for new animal models of Alzheimer's disease. Eur J Pharmacol (2009) 0.85
Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis. Pharm Stat (2009) 0.85